$CVS
CVS HEALTH Corp

2024 Q4 Form 10-Q Financial Statement

#000006480324000034 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $95.43B
YoY Change 6.31%
Cost Of Revenue $52.95B
YoY Change -3.18%
Gross Profit $42.48B
YoY Change 21.11%
Gross Profit Margin 44.52%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.56B
YoY Change 6.9%
Operating Profit $832.0M
YoY Change -77.45%
Interest Expense -$752.0M
YoY Change -208.51%
% of Operating Profit -90.38%
Other Income/Expense, Net $25.00M
YoY Change 13.64%
Pretax Income $105.0M
YoY Change -96.52%
Income Tax $34.00M
% Of Pretax Income 32.38%
Net Earnings $87.00M
YoY Change -96.15%
Net Earnings / Revenue 0.09%
Basic Earnings Per Share $0.07
Diluted Earnings Per Share $0.07
COMMON SHARES
Basic Shares Outstanding 1.258B shares 1.258B shares
Diluted Shares Outstanding 1.259B shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.680B
YoY Change -40.2%
Cash & Equivalents $6.875B
Short-Term Investments $2.805B
Other Short-Term Assets $3.835B
YoY Change 24.76%
Inventory $17.65B
Prepaid Expenses
Receivables $36.18B
Other Receivables $6.732B
Total Short-Term Assets $67.34B
YoY Change -3.99%
LONG-TERM ASSETS
Property, Plant & Equipment $28.96B
YoY Change 122.39%
Goodwill $91.27B
YoY Change 0.01%
Intangibles $27.82B
YoY Change -6.1%
Long-Term Investments $28.94B
YoY Change 33.56%
Other Assets $4.763B
YoY Change -1.28%
Total Long-Term Assets $185.1B
YoY Change 2.16%
TOTAL ASSETS
Total Short-Term Assets $67.34B
Total Long-Term Assets $185.1B
Total Assets $252.4B
YoY Change 0.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $54.87B
YoY Change 12.15%
Accrued Expenses $20.17B
YoY Change -10.62%
Deferred Revenue $174.0M
YoY Change 4.19%
Short-Term Debt $800.0M
YoY Change
Long-Term Debt Due $4.910B
YoY Change 130.3%
Total Short-Term Liabilities $84.63B
YoY Change 3.77%
LONG-TERM LIABILITIES
Long-Term Debt $59.82B
YoY Change 0.07%
Other Long-Term Liabilities $5.484B
YoY Change -12.07%
Total Long-Term Liabilities $5.484B
YoY Change -12.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $84.63B
Total Long-Term Liabilities $5.484B
Total Liabilities $177.3B
YoY Change 0.3%
SHAREHOLDERS EQUITY
Retained Earnings $62.04B
YoY Change 2.81%
Common Stock $18.00M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.94B
YoY Change
Total Liabilities & Shareholders Equity $252.4B
YoY Change 0.45%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $87.00M
YoY Change -96.15%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$745.0M
YoY Change -127.43%
INVESTING ACTIVITIES
Capital Expenditures $670.0M
YoY Change 22.94%
Acquisitions
YoY Change
Other Investing Activities -$2.677B
YoY Change 1084.51%
Cash From Investing Activities -$3.347B
YoY Change 334.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.588B
YoY Change -41.12%
NET CHANGE
Cash From Operating Activities -745.0M
Cash From Investing Activities -3.347B
Cash From Financing Activities -1.588B
Net Change In Cash -5.680B
YoY Change 655.32%
FREE CASH FLOW
Cash From Operating Activities -$745.0M
Capital Expenditures $670.0M
Free Cash Flow -$1.415B
YoY Change -165.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000064803
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
CVS HEALTH CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
05-0494040
dei Entity Address Address Line1
EntityAddressAddressLine1
One CVS Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Woonsocket
dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02895
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
765-1500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CVS
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1258407645 shares
CY2024Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
30925000000 usd
CY2023Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
24657000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
91983000000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
52948000000 usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
349000000 usd
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-01011
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Profit Loss
ProfitLoss
2963000000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7000000 usd
us-gaap Interest Paid Net
InterestPaidNet
2049000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1429000000 usd
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
10557000000 usd
CY2023Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
9876000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
31185000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
29329000000 usd
CY2024Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1169000000 usd
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
11000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1169000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
507000000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
94596000000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
86074000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
268951000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
253593000000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
832000000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3690000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6148000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10370000000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1968000000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
74000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
66000000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
105000000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3019000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4022000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8468000000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.88
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1259000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1287000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1258000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1284000000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1259000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
CY2024Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.665
CY2023Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.995
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.815
CY2024Q3 us-gaap Profit Loss
ProfitLoss
71000000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
2265000000 usd
us-gaap Profit Loss
ProfitLoss
2963000000 usd
us-gaap Profit Loss
ProfitLoss
6321000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
679000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-321000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
544000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
85000000 usd
CY2024Q3 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
-147000000 usd
CY2023Q3 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
181000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
-26000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
167000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-4000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-4000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-12000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
9000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
528000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-146000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
506000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
260000000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
599000000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
2119000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
3469000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
6581000000 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-16000000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7000000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
615000000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2115000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3476000000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
754000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1059000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6558000000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3259000000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36179000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35227000000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
17649000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
18025000000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3835000000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3151000000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
13183000000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16231000000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17252000000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
91272000000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
91272000000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27817000000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29234000000 usd
CY2024Q3 us-gaap Separate Account Assets
SeparateAccountAssets
3334000000 usd
CY2023Q4 us-gaap Separate Account Assets
SeparateAccountAssets
3250000000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4763000000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4660000000 usd
CY2023Q4 us-gaap Assets
Assets
249728000000 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
15713000000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
14897000000 usd
CY2024Q3 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
23917000000 usd
CY2023Q4 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
22874000000 usd
CY2024Q3 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
15237000000 usd
CY2023Q4 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
12049000000 usd
CY2024Q3 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
913000000 usd
CY2023Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1326000000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20174000000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22189000000 usd
CY2024Q3 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1051000000 usd
CY2023Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1141000000 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
800000000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1777000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1258000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1768000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1288000000 shares
CY2024Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
49510000000 usd
CY2023Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
48992000000 usd
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
519000000 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
480000000 shares
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
61604000000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
209000000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-297000000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
74944000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
76461000000 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
162000000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
175000000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75106000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76636000000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252427000000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
249728000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
264538000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
153051000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
80357000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
61658000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
26038000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7247000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7634000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6625000000 usd
us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
600000000 usd
us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
0 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
0 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
5000000000 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
0 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
5000000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4959000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10898000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1706000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2734000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3023000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2013000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
2535000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
2353000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
342000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
242000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
181000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
175000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-22000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-210000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1566000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3655000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1385000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8525000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13305000000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7140000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13375000000 usd
us-gaap Profit Loss
ProfitLoss
2963000000 usd
us-gaap Profit Loss
ProfitLoss
6321000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3450000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3232000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
403000000 usd
CY2023Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations
CY2024Q3 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations
us-gaap Premiums Earned Net
PremiumsEarnedNet
74117000000 usd
CY2024Q3 us-gaap Net Investment Income
NetInvestmentIncome
550000000 usd
CY2023Q3 us-gaap Net Investment Income
NetInvestmentIncome
277000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
1398000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
885000000 usd
CY2024Q3 us-gaap Revenues
Revenues
95428000000 usd
CY2023Q3 us-gaap Revenues
Revenues
89764000000 usd
us-gaap Revenues
Revenues
275099000000 usd
us-gaap Revenues
Revenues
263963000000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
54688000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
151019000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
159679000000 usd
CY2024Q3 us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
29922000000 usd
CY2023Q3 us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
21499000000 usd
us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
85578000000 usd
us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
63729000000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
752000000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
693000000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2200000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2147000000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
71000000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
2265000000 usd
us-gaap Profit Loss
ProfitLoss
6321000000 usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-16000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
23000000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
87000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2261000000 usd
us-gaap Net Income Loss
NetIncomeLoss
2970000000 usd
us-gaap Net Income Loss
NetIncomeLoss
6298000000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.90
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.75
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1290000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1262000000 shares
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
23000000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6875000000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8196000000 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
2805000000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
67343000000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
67858000000 usd
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
28939000000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
23019000000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
12728000000 usd
CY2024Q3 us-gaap Assets
Assets
252427000000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1912000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1741000000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
200000000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
4910000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2772000000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
84627000000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
79189000000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15258000000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16034000000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
59824000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
58638000000 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3632000000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4311000000 usd
CY2024Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3334000000 usd
CY2023Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3250000000 usd
CY2024Q3 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5162000000 usd
CY2023Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5459000000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5484000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6211000000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
177321000000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
173092000000 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
36813000000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
33838000000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
62038000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
260300000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
145469000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
28933000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
1288000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
1174000000 usd
us-gaap Interest Paid Net
InterestPaidNet
2391000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2616000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16062000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5547000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12677000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2013000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2120000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
85000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16492000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-75000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-43000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7066000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19647000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
461000000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
840000000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
152000000 usd
cvs Deferred Income Taxes And Other Items
DeferredIncomeTaxesAndOtherItems
-912000000 usd
cvs Deferred Income Taxes And Other Items
DeferredIncomeTaxesAndOtherItems
-163000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
986000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3920000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-355000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1305000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
850000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
518000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2169000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2466000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
2878000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
4679000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3063000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2047000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7247000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16062000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76636000000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
1124000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-44000000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000000 usd
CY2024Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
2962000000 usd
CY2024Q1 us-gaap Dividends Common Stock
DividendsCommonStock
844000000 usd
CY2024Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-4000000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74150000000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1768000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
159000000 usd
CY2024Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
143000000 usd
CY2024Q2 us-gaap Dividends Common Stock
DividendsCommonStock
846000000 usd
CY2024Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
1000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75111000000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
71000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
528000000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
138000000 usd
CY2024Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
107000000 usd
CY2024Q3 us-gaap Dividends Common Stock
DividendsCommonStock
846000000 usd
CY2024Q3 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-3000000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75106000000 usd
CY2024Q3 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2024Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2024Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71769000000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
2142000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
389000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
122000000 usd
CY2023Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
1962000000 usd
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
781000000 usd
CY2023Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-99000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71580000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
1914000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
345000000 usd
CY2023Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
129000000 usd
CY2023Q2 us-gaap Dividends Common Stock
DividendsCommonStock
786000000 usd
CY2023Q2 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
66000000 usd
CY2023Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-5000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73002000000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
2265000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-146000000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
165000000 usd
CY2023Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
105000000 usd
CY2023Q3 us-gaap Dividends Common Stock
DividendsCommonStock
786000000 usd
CY2023Q3 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-95000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74510000000 usd
CY2023Q3 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q3 cvs Number Of Pharmacy Plan Members
NumberOfPharmacyPlanMembers
90000000 people
CY2024Q3 cvs Number Of Patients Served Per Year
NumberOfPatientsServedPerYear
800000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2023 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2 business
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6875000000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8196000000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
65000000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
90000000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
200000000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
239000000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7140000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8525000000 usd
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9884000000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
11908000000 usd
CY2024Q3 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
15621000000 usd
CY2023Q4 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
15711000000 usd
CY2024Q3 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
3942000000 usd
CY2023Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
3714000000 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
6732000000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3894000000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36179000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35227000000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
346000000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
343000000 usd
CY2023Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1502000000 usd
CY2022Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1219000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
405000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
414000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
217000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
196000000 usd
CY2024Q3 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1690000000 usd
CY2023Q3 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1437000000 usd
CY2023Q3 cvs Premium Deficiency Testing Expense Short Duration Contract Amount
PremiumDeficiencyTestingExpenseShortDurationContractAmount
0 usd
cvs Premium Deficiency Testing Expense Short Duration Contract Amount
PremiumDeficiencyTestingExpenseShortDurationContractAmount
0 usd
CY2024Q3 us-gaap Net Investment Income
NetInvestmentIncome
550000000 usd
CY2024Q3 us-gaap Revenues
Revenues
95428000000 usd
CY2023Q3 us-gaap Net Investment Income
NetInvestmentIncome
277000000 usd
CY2023Q3 us-gaap Revenues
Revenues
89764000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
1398000000 usd
us-gaap Revenues
Revenues
275099000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
885000000 usd
us-gaap Revenues
Revenues
263963000000 usd
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9884000000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
11908000000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
174000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
149000000 usd
CY2024Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1200000000 usd
CY2024Q3 us-gaap Severance Costs1
SeveranceCosts1
293000000 usd
CY2024Q3 cvs Number Of Stores Planned Closure
NumberOfStoresPlannedClosure
271 store
CY2024Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
483000000 usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
124000000 usd
CY2024Q3 cvs Operating Lease Right Of Use Asset Fair Value Disclosure
OperatingLeaseRightOfUseAssetFairValueDisclosure
100000000 usd
CY2024Q3 us-gaap Property Plant And Equipment Fair Value Disclosure
PropertyPlantAndEquipmentFairValueDisclosure
39000000 usd
CY2024Q3 us-gaap Severance Costs1
SeveranceCosts1
293000000 usd
CY2024Q3 us-gaap Payments For Postemployment Benefits
PaymentsForPostemploymentBenefits
0 usd
CY2023Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5000000000 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
2805000000 usd
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
28939000000 usd
CY2024Q3 us-gaap Investments
Investments
31744000000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3259000000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
23019000000 usd
CY2023Q4 us-gaap Investments
Investments
26278000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
26433000000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
510000000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
453000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26490000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22282000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
267000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
836000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21713000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
819000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
816000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
10469000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
10529000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
4827000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4890000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
3127000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
3064000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
26433000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26490000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
493 security
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
871000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
7000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
4554 security
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
6584000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
446000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
5047 security
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
7455000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
453000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1182 security
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1932000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
28000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
7018 security
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
10616000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
808000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
8200 security
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
12548000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
836000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
478000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
5000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
2996000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
109000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
1112000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
90000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
1484000000 usd
CY2024Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
153000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
7455000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
453000000 usd
CY2024Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
557000000 usd
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
432000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1537000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1264000000 usd
CY2024Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
26000000 usd
CY2023Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
13000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
50000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
34000000 usd
CY2024Q3 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
531000000 usd
CY2023Q3 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
419000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
1487000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
1230000000 usd
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
19000000 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-142000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-89000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-345000000 usd
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
550000000 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
277000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
1398000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
885000000 usd
CY2024Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
12000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
51000000 usd
CY2024Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
CY2023Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
47000000 usd
CY2023Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
108000000 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
-3000000 usd
CY2024Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2322000000 usd
CY2023Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1171000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5203000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3503000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
16000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
2000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
30000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
7000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
39000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
110000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
162000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
294000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
47000000 usd
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
47000000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
42000000 usd
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2024 and 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,067 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,521 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,237 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive income (loss) on the unaudited condensed consolidated balance sheets. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the nine months ended September 30, 2024 and 2023 in the table above exclude $70 million and $62 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $142 million and $163 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. Total incurred health care costs for the nine months ended September 30, 2024 also exclude $670 million for premium deficiency reserves related to the Company’s Medicare, individual exchange and Medicaid product lines.</span></div>
CY2023Q4 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
12049000000 usd
CY2023Q4 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
5000000 usd
CY2023Q4 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
23000000 usd
CY2023Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
12067000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
0 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
1098000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
85541000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
64183000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-845000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-679000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
84696000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
63504000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
71356000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
52952000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
10886000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
9207000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
82242000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
62159000000 usd
CY2024Q3 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
14521000000 usd
CY2023Q3 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
12572000000 usd
CY2024Q3 cvs Premium Deficiency Reserve Liability
PremiumDeficiencyReserveLiability
670000000 usd
CY2023Q3 cvs Premium Deficiency Reserve Liability
PremiumDeficiencyReserveLiability
0 usd
CY2024Q3 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
65000000 usd
CY2023Q3 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
4000000 usd
CY2024Q3 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
19000000 usd
CY2023Q3 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
26000000 usd
CY2024Q3 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
15237000000 usd
CY2023Q3 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
12550000000 usd
CY2024Q3 cvs Premium Deficiency Reserve Liability
PremiumDeficiencyReserveLiability
670000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-845000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-679000000 usd
CY2024Q3 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
11000000000.0 usd
CY2023Q4 us-gaap Policyholder Funds
PolicyholderFunds
332000000 usd
CY2022Q4 us-gaap Policyholder Funds
PolicyholderFunds
345000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
2000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
1000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
1000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
2000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
9000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
23000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
8000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
9000000 usd
cvs Policyholder Account Balance Change In Net Unrealized Gains Losses
PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses
17000000 usd
cvs Policyholder Account Balance Change In Net Unrealized Gains Losses
PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses
-4000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-18000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-23000000 usd
CY2024Q3 us-gaap Policyholder Funds
PolicyholderFunds
331000000 usd
CY2023Q3 us-gaap Policyholder Funds
PolicyholderFunds
303000000 usd
CY2024Q3 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0430
CY2023Q3 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0440
CY2024Q3 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2023Q3 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2024Q3 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
310000000 usd
CY2023Q3 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
324000000 usd
CY2023Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3250000000 usd
CY2022Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3228000000 usd
us-gaap Separate Account Liability Premium And Deposit
SeparateAccountLiabilityPremiumAndDeposit
661000000 usd
us-gaap Separate Account Liability Premium And Deposit
SeparateAccountLiabilityPremiumAndDeposit
657000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
203000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
7000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
706000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
714000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
327000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
42000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-8000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-4000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-3000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-10000000 usd
CY2024Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3334000000 usd
CY2023Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3200000000 usd
CY2024Q3 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2209000000 usd
CY2023Q3 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2136000000 usd
CY2024Q3 us-gaap Commercial Paper
CommercialPaper
800000000 usd
CY2023Q4 us-gaap Commercial Paper
CommercialPaper
200000000 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1373000000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1391000000 usd
CY2024Q3 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
66087000000 usd
CY2023Q4 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
62160000000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
174000000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
186000000 usd
CY2024Q3 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
727000000 usd
CY2023Q4 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
736000000 usd
CY2024Q3 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
65534000000 usd
CY2023Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
61610000000 usd
CY2024Q3 us-gaap Commercial Paper
CommercialPaper
800000000 usd
CY2023Q4 us-gaap Commercial Paper
CommercialPaper
200000000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
4910000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2772000000 usd
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
59824000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
58638000000 usd
CY2024Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5000000000 usd
CY2024Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.665
CY2023Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.995
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.815
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
528000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-146000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
506000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
260000000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
87000000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
87000000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2261000000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2261000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2970000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2970000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6298000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
6298000000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1259000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1287000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1258000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1284000000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1259000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1290000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1262000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.90
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.88
CY2024Q3 cvs Guarantor Obligations Number Of Leases
GuarantorObligationsNumberOfLeases
61 lease
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2024Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
94878000000 usd
CY2024Q3 us-gaap Net Investment Income
NetInvestmentIncome
550000000 usd
CY2024Q3 us-gaap Revenues
Revenues
95428000000 usd
CY2024Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
2547000000 usd
CY2023Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
89487000000 usd
CY2023Q3 us-gaap Net Investment Income
NetInvestmentIncome
277000000 usd
CY2023Q3 us-gaap Revenues
Revenues
89764000000 usd
CY2023Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4456000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
273701000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
1398000000 usd
us-gaap Revenues
Revenues
275099000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
9248000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
263078000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
885000000 usd
us-gaap Revenues
Revenues
263963000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13307000000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
832000000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3690000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6148000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10370000000 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
507000000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
509000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1522000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1396000000 usd
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
19000000 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-142000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-89000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-345000000 usd
CY2024Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
41000000 usd
CY2023Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
94000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
203000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
294000000 usd
CY2024Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1169000000 usd
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
11000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1169000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
507000000 usd
CY2024Q3 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
17000000 usd
CY2023Q3 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
10000000 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
17000000 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
46000000 usd
CY2024Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2023Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-100000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
349000000 usd
CY2024Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
2547000000 usd
CY2023Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4456000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
9248000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13307000000 usd
CY2024Q3 cvs Number Of Stores Planned Closure
NumberOfStoresPlannedClosure
271 store
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000064803-24-000034-index-headers.html Edgar Link pending
0000064803-24-000034-index.html Edgar Link pending
0000064803-24-000034.txt Edgar Link pending
0000064803-24-000034-xbrl.zip Edgar Link pending
a09302024ex151.htm Edgar Link pending
a09302024ex311.htm Edgar Link pending
a09302024ex312.htm Edgar Link pending
a09302024ex321.htm Edgar Link pending
a09302024ex322.htm Edgar Link pending
cvs-20240930.htm Edgar Link pending
cvs-20240930.xsd Edgar Link pending
cvs-20240930_g1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
cvs-20240930_cal.xml Edgar Link unprocessable
cvs-20240930_def.xml Edgar Link unprocessable
cvs-20240930_lab.xml Edgar Link unprocessable
cvs-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cvs-20240930_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending